UiPath (NYSE:PATH) Price Target Raised to $15.00 at DA Davidson

UiPath (NYSE:PATH) had its target price upped by DA Davidson from $13.00 to $15.00 in a report published on Friday morning, Benzinga reports. They currently have a neutral rating on the healthcare company’s stock. DA Davidson also issued estimates for UiPath’s Q3 2025 earnings at ($0.08) EPS.

Other analysts have also issued research reports about the company. Wells Fargo & Company upped their target price on UiPath from $14.00 to $15.00 and gave the company an equal weight rating in a report on Friday. Canaccord Genuity Group lowered their price objective on shares of UiPath from $30.00 to $19.00 and set a buy rating on the stock in a research note on Friday, May 31st. BMO Capital Markets lifted their target price on shares of UiPath from $14.00 to $15.00 and gave the stock a market perform rating in a research report on Friday. Mizuho lowered their price target on shares of UiPath from $25.00 to $14.00 and set a neutral rating on the stock in a research report on Thursday, May 30th. Finally, KeyCorp reissued a sector weight rating on shares of UiPath in a research note on Thursday, May 30th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $17.71.

UiPath Stock Up 1.8 %

Shares of PATH opened at $12.19 on Friday. The company has a market capitalization of $6.98 billion, a PE ratio of -76.19 and a beta of 0.87. UiPath has a 52-week low of $10.37 and a 52-week high of $27.87. The company has a 50-day simple moving average of $12.19 and a 200-day simple moving average of $16.54.

UiPath (NYSE:PATH) last issued its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The company had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.89%. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted ($0.09) earnings per share. On average, research analysts anticipate that UiPath will post -0.22 EPS for the current year.

Hedge Funds Weigh In On UiPath

Several institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC purchased a new stake in UiPath in the 2nd quarter valued at about $155,000. Advisory Alpha LLC acquired a new position in UiPath during the second quarter worth approximately $131,000. Capital Impact Advisors LLC raised its stake in UiPath by 162.9% during the second quarter. Capital Impact Advisors LLC now owns 36,400 shares of the healthcare company’s stock worth $462,000 after purchasing an additional 22,553 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of UiPath by 15.4% in the 2nd quarter. Sunbelt Securities Inc. now owns 20,970 shares of the healthcare company’s stock valued at $266,000 after purchasing an additional 2,792 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of UiPath by 2,495.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 682,078 shares of the healthcare company’s stock valued at $8,649,000 after buying an additional 655,798 shares during the period. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.